WO2007090673A2 - Kleber für medizinische anwendungen und mittel zur blutstillung - Google Patents
Kleber für medizinische anwendungen und mittel zur blutstillung Download PDFInfo
- Publication number
- WO2007090673A2 WO2007090673A2 PCT/EP2007/001131 EP2007001131W WO2007090673A2 WO 2007090673 A2 WO2007090673 A2 WO 2007090673A2 EP 2007001131 W EP2007001131 W EP 2007001131W WO 2007090673 A2 WO2007090673 A2 WO 2007090673A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adhesive
- kit
- dihydroxyaromatics
- individual components
- zeolite granules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J175/00—Adhesives based on polyureas or polyurethanes; Adhesives based on derivatives of such polymers
- C09J175/04—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
- C08G18/428—Lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/64—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63
- C08G18/6415—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63 having nitrogen
- C08G18/6446—Proteins and derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J189/00—Adhesives based on proteins; Adhesives based on derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the invention relates to adhesives for medical applications and agents for hemostasis.
- the invention relates to a kit for producing an adhesive which is suitable for bonding together hard and soft tissues, sealing wounds, and the adhesive itself and its uses in the medical field.
- the kit or the associated adhesive comprises, as individual components, substrates of polyphenol oxidase and polyphenol oxidases as such.
- the invention is directed to new hemostyptics, as well as to the combined use of hemostyptics and adhesives in wound closure.
- EP 0 947 142 discloses increasing the molecular weight of proteins by their cross-linking by multi-copper enzymes. The described increase in the molecular weight of the substrate proteins occurred after 17 hours of incubation.
- the proteins crosslinked by means of the method according to EP 0 947 142 are particularly suitable for use in foods, e.g. to change the consistency of sausage. Cross-linking of proteins by substituted dihydroxyaromatics is not disclosed in EP 0 947 142.
- microporous biopolymers or biopolymers with a large internal surface These absorb water, resulting in a concentration of blood cells and coagulation factors.
- Polysaccharides which consist of poly-N-acetyl-glucosamines or chitosan have proved to be particularly advantageous. These are included, for example, in the skeleton of insects, but also in algae.
- Biopolymers such as gelatin, collagen, fibrin sponges or oxidized cellulose have a large internal surface area. Due to the absorption to this large area, a concentration of coagulation factors occurs.
- the aluminosilicate synthesis products hitherto used for haemostasis are alkali metal and alkaline earth aluminum silicates of different composition
- Synthetic lithium aluminosilicates (EP 1176991 A1, WO 00/69480) have been developed especially for wound care and are sold under the trade name CERDAC.
- CERDAC Synthetic lithium aluminosilicates
- the present problem now is to solve the problems mentioned in the prior art by products which have efficient adhesive properties for hard and soft tissue.
- systems such as adhesives, should be provided, which make it possible to quench severely bleeding wounds and / or to connect bone parts to each other or to bone sections with implants.
- adhesives that allow soft tissue to be associated with bone, such as cartilage grafts.
- the possibilities for wound closure found should preferably also be transferable to chronic and infected wounds.
- the finding of the present invention is that polymers which have at least one free amino group can be crosslinked by means of bridge molecules using (lignolytic) polyphenol oxidases to form covalent bonds with one another and / or with the body's own tissue and thus can be used as hard and soft tissue adhesives.
- a further finding of the present invention is that specifically prepared natural zeolites cause rapid hemostasis.
- the present invention is directed in a first embodiment to a kit which comprises the following individual components: a) polymers having at least one free amino group, b) bridging molecules selected from the group consisting of monocyclic ortho-dihydroxyaromatics, monocyclic para-dihydroxyaromatics, bicyclic monohydroxyaromatics , polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic dihydroxyaromatics, bicyclic trihydroxyaromatics, polycyclic trihydroxyaromatics, and mixtures thereof, and c) polyphenol oxidases, in particular lignolytic polyphenol oxidases, the two individual components (components b) and c)), ie the group consisting of monocyclic ortho-dihydroxyaromatics, monocyclic para-dihydroxyaromatics, bicyclic monohydroxyaromatics , polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic dihydroxyaromatic
- Bridge molecules are not in contact with the polyphenol oxidases, particularly lignolytic polyphenol oxidases.
- a kit is understood to mean, in particular, a packaging which makes it possible to store the individual components next to one another in such a way that they are not in contact.
- at least the bridging molecules (component b)) must be separated from the (lignolytic) polyphenol oxidases (component c)), so that an early and undesired reaction is avoided. Consequently, a mixture of components a) and b) and / or components a) and c) is possible.
- both individual components can preferably be stored in different vessels or chambers. This also applies to the case if one or both of the individual components b) and c) is mixed with the polymer a).
- a syringe is conceivable which makes it possible to deliver the two individual components, ie the bridge molecules and the (lignolytic) polyphenol oxidases, separately from one another via two cannulas. It is preferred that the two individual components, ie the bridge molecules and the (lignolytic) polyphenol oxidases, are present in the syringe in different chambers.
- the kit comprises at least two syringes, one containing the bridge molecules and the other the (lignolytic) polyphenol oxidases.
- the kit is a two-component syringe, preferably already with an attached mixing extruder. This allows a particularly accurate dosage and easy handling.
- kits comprises as individual component a) polymers which contain at least one free amino group.
- free amino group in the present invention is meant an amino group which is not part of the polymer chain but represents a residue of the polymer chain. After these polymers are present in the kit, they are not part of the human body.
- the polymers are preferably polymers which comprise more than one amino group, ie polymers containing amino groups, such as peptides.
- the peptides ie in oligopeptides and proteins
- the peptides are lysine-containing.
- lysine-containing oligopeptides are used. It is also conceivable that the peptide is collagen.
- the polymer is a peptide
- the compound formed by reaction of the components is biodegradable.
- peptide sequences that contain the amino acids relevant for an adhesive effect By linking peptide sequences that contain the amino acids relevant for an adhesive effect, a very strong bond is formed, which can however be absorbed in the course of the healing process.
- the initial hardening phase, combined with high adhesive properties, and the time-dependent slow absorption in the body in advanced healing processes are of particular advantage, since in the splice increasingly endogenous tissue is incorporated.
- the peptide used is both an oligopeptide (2 to about 100 amino acids in length, preferably about 4 to about 20 amino acids in length or about 6 to about 10 amino acids in length) and a protein (protein, about 100 up to about 5000 amino acids in length, preferably 100-1000 or 100-200 amino acids in length).
- the peptide has a length of 10-1000 amino acids.
- the peptide may have a molecular weight of about 1 to about 100 or about 200 kDa, more preferably about 2 to about 50 kDa, or about 5 to about 20 kDa. It may be modified or substituted, e.g. glycosylated.
- modified or atypical amino acids such as hydroxyoxy may also be present in the oligopeptide.
- D-amino acids instead of or in addition to L-amino acids is possible and slows down the degradation of the peptide.
- the amino groups may preferably be primary or secondary amino groups. However, especially reactive are primary amino groups. At least one of the reactive groups of the peptide is preferably part of a diamino acid, eg from lysine.
- the peptide therefore preferably comprises at least one diamino acid, preferably at least 2, 3, 4, 5 or more diamino acids.
- lysine-containing peptides oligopeptides or proteins are used.
- amino acids such as arginine, asparagine, glutamine or histidine, carry reactive amino groups that can react with the dihydroxyaromatic.
- the amino groups are particularly suitable for the crosslinking reaction between peptide and bridging molecule.
- hydroxyl groups or mercapto groups in the peptide may also contribute to the crosslinking reaction.
- the peptide therefore preferably comprises at least one amino acid with a hydroxyl group, ie in particular serine, threonine or tyrosine or a mercapto group, e.g. Cysteine.
- Hydroxylysine or polyphenolic amino acid building blocks, as present in the MAPs can also be present in the peptides used according to the invention.
- an advantage of the present invention is that the presence of these specific amino acid building blocks and thus the use of MAPs is not absolutely necessary. Therefore, in a preferred embodiment, the polymer is free of polyphenolic amino building blocks, i. free from MAPs.
- the peptides used can therefore be e.g. be made recombinantly without further ado.
- the crosslinking resulting from reaction of the bridging molecules with the peptide also depends on how high the proportion of available reactive groups in the peptide is.
- Good adhesive properties can be achieved from a proportion of amino acids of the peptide carrying a reactive amino group (eg diamino acids such as lysine) of at least 10%.
- the proportion of polymer structure elements carrying an amino group is preferably at least about 10%. Even more preferably, however, the proportion of these amino acids or structural elements is higher, at least 20%, at least 30%, at least 40 or at least 50% or even at least 80 to 100%.
- Naturally occurring peptides and proteins, eg albumin or casein can be used, for example MAPs are particularly suitable.
- amino acids of the peptide are lysine.
- Lysine and another amino acid can e.g. be arranged as a repeating dipeptide unit.
- a different sequence or the inclusion of other amino acids in particular arginine, asparagine, glutamine or histidine (instead of lysine or in addition), serine or threonine (instead of tyrosine or in addition), of cysteine or other amino acids is possible.
- a length of the peptide of about 10-20 amino acids or a mixture of peptides of different chain length is particularly preferred.
- nj values between 5 and 40, such as 5, 10 or 20 can assume.
- kit comprises bridging molecules which cause crosslinking of polymers having at least one free amino group (such as diamino acids) as defined above.
- substituted dihydroxyaromatics and / or substrates of the (lignolytic) polyphenol oxidases, such as laccases, are suitable as bridging molecules.
- monocyclic ortho-dihydroxyaromatics monocyclic para-dihydroxyaromatics, bicyclic monohydroxyaromatics, polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatic, polycyclic Dihydroxyaromaten, bicyclic Trihydroxyaromaten, polycyclic Trihydroxyaromaten, or their mixtures used.
- the hydroxyaromatic compounds according to the invention are not part of a polymer chain.
- aromatics are further substituted.
- Preferred functional groups are substituents selected from the group consisting of halogen, sulfo, sulfonic, sulfamino, sulfanyl, amino, amido, azo, imino and hydroxy. It is observed in particular that substituted aromatics, in particular substituted dihydroxyaromatics, surprisingly have particularly favorable polymerization properties, in particular a rapid polymerization, a lower self-coupling and a good strength of the bond is achieved. A suitable substitution of the aromatics can even lead to monohydroxyaromatics being suitable for crosslinking as bridging molecule. Substituted means in the context of this invention, in particular, that in addition to the hydroxyl groups 1, 2, 3 or 4 further radicals are attached to the aromatic compounds. On the other hand, monohydroxylated biaryl compounds are also suitable.
- n 0-10, preferably 0 or 1, in particular 0,
- Alkyl means branched or unbranched aliphatic hydrocarbon chains, preferably of 1-20, more preferably 1-6 carbons, e.g. Methyl, ethyl, propyl, butyl, isobutyl, n-pentyl, n-hexyl
- the phenyls of the formula 5 may be substituted, for example in the ortho position to an OH group with CH 3 , CHO, COCH 3 , CONH 2 , CON-alkyl, CON-alkyl-OH, COOH, COO-alkyl, alkyl, substituted aromatic, in particular CON-alkyl or COO-alkyl, and / or in the metha position to an OH group with CH 3 , alkyl, substituted aromatic, in particular CH 3 .
- kits comprise as further individual component polyphenol oxidases, such as lignolytic polyphenol oxidases, in particular laccase (EC 1.10.3.2).
- Laccases are known in the art. They can be derived from plants, fungi, bacteria or insects or derived from natural enzymes. The laccases used in the invention may be recombinantly produced or purified. In this case, a particular purity of the laccase is generally not required, given if supernatants lignolytic fungi can be used. For medical applications, however, is a significant separation of microbiological substances such as
- laccases from the genera Aspergillus, Neurospora, Podospora, Botrytis, Collybia, Fomes, Lentinus, Pleurotus, Pycnoporus, Pyricularia, Trametes, Rhizoctonia, Coprinus, Psatyrella, Myceliophthora, Schtalidium, Polyporus, Phlebia or Coriolus.
- laccases are disclosed, for example, in EP 0 947 142.
- the kit is characterized in particular by the fact that the adhesive reaction is not restricted to specific naturally occurring peptides acting as a bridging molecule, but rather to a broad spectrum of bridging molecules, on the one hand, and of peptides, such as oligopeptides or proteins, on the other hand, can be used.
- kits pre-optimized in proportions appropriate to the particular use.
- the combination used in the kit may contain other additives and adjuvants, e.g. Fillers such as collagen, albumin, hyaluronic acid or the like.
- Fillers such as collagen, albumin, hyaluronic acid or the like.
- the total amount of single component a), such as peptide, and bridging molecule is about 50-90%.
- the essential components of the kit are preferably dissolved with one or more aqueous solvents.
- the solvent is non-toxic and biocompatible.
- Preferred as a solvent for biological applications is a phosphate buffer such as
- Calcium phosphate or sodium phosphate buffer or PBS may also be an organic solvent such as DMSO or a mixture of an aqueous and an organic solvent.
- organic solvent such as DMSO or a mixture of an aqueous and an organic solvent.
- the combination or its components can only be included in the solvent prior to use and introduced into the kit.
- the consistency of the components used in the kit does not have to be liquid, but may have a pasty consistency.
- the viscosity and flowability of the individual components used can be adjusted depending on, for example, the length of the wound to be fixed and the wound gap depth or the substrates to be bonded. In addition to the length of the peptides / polymers used, the amount of solvent also has an influence on these parameters. Also additives such as thixotropic agents can be used to adjust viscosity and flowability be used. Typically, for bonding hard tissue, a combination of higher viscosity is used than for gluing soft tissue.
- the pH is preferably 2-10, especially 5-7.
- the reaction can proceed at about 2-80 ° C, but preferably a temperature of about 20-37 ° C or 25-3O 0 C.
- the adhesive reaction can be carried out using a kit at room temperature / body temperature.
- the (lignolytic) polyphenol oxidase such as laccase
- Sterilization of the kit or its individual components can advantageously be achieved without structural change. It is possible, e.g. a sterile filtration of solutions. However, sterilization by way of gamma radiation is preferred since it can already be packed and therefore no aseptic filling is necessary. The loss of activity of the (lignolytic) polyphenol oxidase, such as laccase, by the gamma sterilization, which can be up to 50%, can be easily compensated by a correspondingly higher starting concentration.
- the above-defined kit is used as a medicament.
- the present invention relates to an adhesive with the individual components described above. Consequently, the adhesive comprises the following individual components: a) polymers having at least one free amino group, where the polymers are not part of the human body, b) bridging molecules selected from the group consisting of monocyclic ortho-dihydroxyaromatics, monocyclic para
- Dihydroxyaromatics bicyclic monohydroxyaromatics, polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic dihydroxyaromatics, bicyclic trihydroxyaromatics, polycyclic trihydroxyaromatics, and mixtures thereof, and c) polyphenol oxidases, in particular lignolytic polyphenol oxidases, wherein the two individual components (components b) and c)), i. the bridging molecules are in contact with the polyphenol oxidases, in particular the lignolytic polyphenol oxidases, i. are mixed together.
- the adhesive comprises as individual component a) polymers which contain at least one free amino group.
- free amino group in the present invention is meant an amino group which is not part of the polymer chain but represents a residue of the polymer chain.
- the polymers of the adhesive are polymers that are not part of the human body are.
- the polymers are polymers comprising more than one amino group, ie, amino group-rich polymers such as peptides.
- the peptides are lysine-containing.
- lysine-containing oligopeptides are used. It is also conceivable that the peptide is collagen.
- the polymer is a peptide
- the compound formed by reaction of the components is biodegradable.
- Amino acids contain, creates a very strong bond, but which can be absorbed in the course of the healing process.
- the initial hardening phase, combined with high adhesive properties, and the time-dependent slow absorption in the body in advanced healing processes are of particular advantage, since in the splice increasingly endogenous tissue is incorporated.
- the peptide used is both an oligopeptide (2 to about 100 amino acids in length, preferably about 4 to about 20 amino acids in length or about 6 to about 10 amino acids in length) and a protein (protein, about 100 up to about 5000 amino acids in length, preferably 100-1000 or 100-200 amino acids in length).
- the peptide has a length of 10-1000 amino acids.
- the peptide may have a molecular weight of about 1 to about 100 or about 200 kDa, more preferably about 2 to about 50 kDa, or about 5 to about 20 kDa. It may be modified or substituted, e.g. glycosylated.
- modified or atypical amino acids such as hydroxyoxy may also be present in the oligopeptide.
- D dioethylated amino acids
- the amino groups may preferably be primary or secondary amino groups. However, especially reactive are primary amino groups. At least one of the reactive groups of the peptide is preferably part of a diamino acid, for example of lysine.
- the peptide therefore preferably comprises at least one diamino acid, preferably at least 2, 3, 4, 5 or more diamino acids.
- lysine-containing peptides oligopeptides or proteins are used.
- amino acids such as arginine, asparagine, glutamine or histidine, carry reactive amino groups that can react with the dihydroxyaromatic.
- amino groups in particular the amino groups provided by the diamino acid, are responsible for the crosslinking reaction between peptide and
- hydroxyl groups or mercapto groups in the peptide may also contribute to the crosslinking reaction.
- the peptide therefore preferably comprises at least one amino acid with a hydroxyl group, ie in particular serine, threonine or tyrosine or a mercapto group, e.g. Cysteine.
- Hydroxylysine or polyphenolic amino acid building blocks, as present in the MAPs can also be present in the peptides used according to the invention.
- an advantage of the present invention is that the presence of these specific amino acid building blocks and thus the use of MAPs is not absolutely necessary. Therefore, in a preferred embodiment, the polymer is free of polyphenolic amino building blocks, i. free from MAPs.
- the peptides used can therefore be e.g. be made recombinantly without further ado.
- the crosslinking resulting from reaction of the bridging molecules with the peptide also depends on how high the proportion of available reactive groups in the peptide is.
- Good adhesive properties can be achieved from a proportion of amino acids of the peptide carrying a reactive amino group (eg diamino acids such as lysine) of at least 10%.
- the proportion of polymer structural elements bearing an amino group is preferably at least about 10%. Even more preferably, however, the proportion of these amino acids or structural elements is higher, at least 20%, at least 30%, at least 40 or at least 50% or even at least 80 to 100%.
- Naturally occurring peptides and proteins, eg albumin or casein can be used, for example MAPs are particularly suitable.
- amino acids of the peptide are lysine.
- Lysine and another amino acid can e.g. be arranged as a repeating dipeptide unit.
- a different sequence or the inclusion of other amino acids in particular arginine, asparagine, glutamine or histidine (instead of lysine or in addition), serine or threonine (instead of tyrosine or in addition), of cysteine or other amino acids is possible.
- a length of the peptide of about 10-20 amino acids or a mixture of peptides of different chain length is particularly preferred.
- these are polymers consisting exclusively of two amino acids, for example (lysine-tyrosine) n , where n values between 5 and 40, such as 5, 10 or 20, can be assumed.
- the adhesive comprises bridging molecules which cause crosslinking of polymers having at least one free amino group (such as diamino acids) as defined above.
- substituted dihydroxyaromatics and / or substrates of the (lignolytic) polyphenol oxidases, such as laccases are suitable as bridging molecules. Accordingly, monocyclic ortho-dihydroxyaromatics, monocyclic para-dihydroxyaromatics, bicyclic monohydroxyaromatics, polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic dihydroxyaromatics, bicyclic trihydroxyaromatics, polycyclic trihydroxyaromatics or mixtures thereof are used. In contrast to the known shell adhesives, the hydroxyaromatic compounds according to the invention are not part of a polymer chain.
- aromatics are further substituted.
- Preferred functional groups are substituents selected from the group consisting of halogen, sulfo, sulfonic, sulfamino, sulfanyl, amino, amido, azo, imino and hydroxy. It is observed in particular that substituted aromatics, in particular substituted dihydroxyaromatics, surprisingly have particularly favorable polymerization properties, in particular a rapid polymerization, a lower self-coupling and a good strength of the bond is achieved. A suitable substitution of the aromatics can even lead to monohydroxyaromatics being suitable for crosslinking as bridging molecule. Substituted means in the context of this invention, in particular, that in addition to the hydroxyl groups 1, 2, 3 or 4 further radicals are attached to the aromatic compounds. On the other hand, monohydroxylated biaryl compounds are also suitable.
- n 0-10, preferably 0 or 1, in particular 0,
- Ri OH or NH 2 or Hal, preferably OH, Cl or Br, in particular OH,
- R 2 H, CH 3 , CHO, COCH 3 , CONH 2 , CON-alkyl, CON-alkyl-OH, COOH, COO-
- Alkyl alkyl, substituted aromatic, in particular CON-alkyl or COO-alkyl, and
- R 3 H, CH 3 , alkyl, substituted aromatic, especially H or CH 3 .
- Alkyl means branched or unbranched aliphatic hydrocarbon chains, preferably of 1-20, more preferably 1-6 carbons, e.g. Methyl, ethyl, propyl, butyl, isobutyl, n-pentyl, n-hexyl
- the phenyls of the formula 5 may be substituted, for example in the ortho position to an OH group with CH 3 , CHO, COCH 3 , CONH 2 , CON-alkyl, CON-alkyl-OH, COOH, COO-alkyl, alkyl, substituted aromatic, in particular CON-alkyl or COO-alkyl, and / or in the metha position to an OH group with CH 3 , alkyl, substituted aromatic, in particular CH 3 .
- the adhesive comprises, as a further individual component, polyphenol oxidases, such as lignolytic polyphenoloxydases, in particular laccase (EC 1.10.3.2).
- Laccases are known in the art. They can be derived from plants, fungi, bacteria or insects or derived from natural enzymes. The laccases used in the invention may be recombinantly produced or purified. In this case, a particular purity of the laccase is generally not required, given if supernatants lignolytic fungi can be used. For medical applications, however, is a significant separation of microbiological substances such as
- laccases from the genera Aspergillus, Neurospora, Podospora, Botrytis, Collybia, Fontes, Lentinus, Pleurotus, Pycnoporus, Pyricularia, Trametes, Rhizoctonia, Coprinus, Psatyrella, Myceliophthora, Schtalidium, Polyporus, Phlebia or Coriolus.
- laccases from the genera Aspergillus, Neurospora, Podospora, Botrytis, Collybia, Fontes, Lentinus, Pleurotus, Pycnoporus, Pyricularia, Trametes, Rhizoctonia, Coprinus, Psatyrella, Myceliophthora, Schtalidium, Polyporus, Phlebia or Coriolus.
- laccases from the genera Aspergillus, Neurospora, Podospora, Botrytis, Collybia, Fontes, Lentinus, Pleu
- the adhesive is characterized in particular by the fact that the adhesive reaction is not restricted to specific naturally occurring peptides acting as a bridging molecule, but rather to a broad spectrum of bridging molecules, on the one hand, and of peptides, such as oligopeptides, or proteins, on the other hand, can be used.
- the adhesive can be adapted to the respective specific task by the optimization of the quantity ratios to be carried out in preliminary tests.
- the constituents of the adhesive are present in a previously optimized ratio which is appropriate for the particular use.
- the combination used in the adhesive may contain other additives and adjuvants, e.g. Fillers such as collagen, albumin, hyaluronic acid or the like.
- Fillers such as collagen, albumin, hyaluronic acid or the like.
- the total amount of single component a), such as peptide, and bridging molecule is about 50-90%.
- the essential components of the adhesive are preferably dissolved with one or more aqueous solvents.
- the solvent is non-toxic and biocompatible.
- Preferred as a solvent for biological applications is a phosphate buffer such as
- Calcium phosphate or sodium phosphate buffer or PBS may also be an organic solvent such as DMSO or a mixture of an aqueous and an organic solvent.
- organic solvent such as DMSO or a mixture of an aqueous and an organic solvent.
- the combination or its components can only be included in the solvent prior to use.
- the consistency of the individual components of the adhesive used need not be liquid, but may have a pasty consistency.
- the viscosity and flowability of the individual components used and / or of the adhesive can be adjusted depending on, for example, the length of the wound to be fixed and the wound gap depth or the substrates to be bonded. In addition to the length of the peptides / polymers used, the amount of solvent also has an influence on these parameters. Also additives such as thixotropic agents can be used to adjust of viscosity and flowability can be used. Typically, for bonding hard tissue, a combination of higher viscosity is used than for gluing soft tissue.
- the pH is preferably 2-10, especially 5-7.
- the reaction may proceed at about 2-80 ° C, but is preferably a temperature of about 20-37 ° C or 25-30 0 C.
- the adhesive reaction can be carried out by means of adhesive at room temperature / body temperature.
- the (lignolytic) polyphenol oxidase such as laccase
- a sterilization of the adhesive or its individual components can be advantageously achieved without structural change. It is possible, e.g. a sterile filtration of solutions. However, sterilization by way of gamma radiation is preferred since it can already be packed and therefore no aseptic filling is necessary.
- the loss of activity of the lignolytic) polyphenol oxidase, such as laccase, by the gamma sterilization, which can be up to 50%, can be easily compensated by a correspondingly higher starting concentration.
- the above-defined adhesive is used as a medicament.
- Classification as a pharmaceutical preparation or as a medical device is also possible, depending on national law. These terms are interchangeable for the purposes of describing the invention.
- the uses of the kit and adhesive according to the invention are explained in more detail below.
- a finding of the present invention is that by means of bridging molecules using (lignolytic) polyphenol oxidases, such as laccase, with formation of covalent bonds with polymers containing at least one free
- the present invention is directed to the use of a kit as defined above for sealing wounds.
- the kit or the adhesive has only the individual components b) and c) to cause sticking of wounds or the like, as described below.
- the present invention is also directed to the use of a kit comprising the individual components a) bridging molecules selected from the group consisting of monocyclic ortho-dihydroxyaromatics, monocyclic para-dihydroxyaromatics, bicyclic
- Monohydroxyaromatics polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic dihydroxyaromatics, bicyclic trihydroxyaromatics, polycyclic trihydroxyaromatics, and mixtures thereof, and b) polyphenol oxidases, especially lignolytic ones
- Polyphenol oxidases the two individual components (components a) and b)), i. the bridge molecules are not in contact with the polyphenol oxidases, in particular lignolytic polyphenol oxidases, for the preparation of an adhesive for
- kits or an adhesive is understood as meaning a kit or an adhesive comprising the two individual components “bridge molecules” and “polyphenol oxidases” or the three individual components “polymers having at least one free amino group", “bridging molecules” and “polyphenol oxidases”. comprises, wherein a kit or an adhesive with the three individual components just mentioned is preferred.
- the kit and / or adhesive can be used to glue hard or soft tissue.
- connective tissue, skin, tendon, organ, blood vessel and / or nerve (soft tissue) and / or tooth and / or bone (hard tissue) may be adhered.
- various tissues can be glued together, e.g. Tendons and bones.
- a particularly preferred application is in the bonding of wound edges or in the adhesion of ruptures of various organs, such as liver, kidney or spleen.
- the care of surgically placed wounds e.g. after the removal of tumors, is possible with the kit and / or adhesive according to the invention.
- Further fields of use are in plastic, reconstructive and / or cosmetic surgery, in particular for preventing the formation of scars, which is induced when suturing wounds
- kits and / or adhesive are flexible, over a certain time resorbable sealing of anastomoses and patches on vessels or on hollow organs.
- the kit and / or adhesive is also suitable for the fixation of drug-delivery devices and porous support structures or membranes for potential use in regenerative medicine (tissue engineering).
- a bond can also be made with surfaces of non-biogenic origin, provided they carry free amino groups.
- Free amino groups can be obtained on such surfaces of non-biogenic origin by processes known in the art, eg plasma processes (Schröder, et al., Im proved low-pressure plasma-assisted amino functionalization of polymers, Weinheim, Germany, Weinheim: Wiley-VCH, 2005; Schröder et al., Plasma-Induced Surface Functionalization of Polymeric Biomaterials in Ammonia Plasma, Contrib. Plasma Phys. 41, 2001, 562-572; Meyer-Plath et al, Current trends in biomaterial surface functionalization - nitrogen-containing plasma-assisted processes with enhanced selectivity, Vacuum 71, 2003, 391-406).
- the surfaces e.g. implants or drug-delivery devices to be attached to the kit and / or adhesive to surrounding tissue should have a content of at least about 2% free amino groups.
- the term surface describes not only flat surfaces, but boundary layers of a solid substrate in any shape. Substrates can thus e.g. also be beads or complex shaped surfaces.
- the invention likewise relates to an adhesive method that can be used in an aqueous environment using the above-mentioned kit and / or adhesive, which leads to a solid, crosslinked resorbable compound.
- a solid compound is formed by a (lignolytic) polyphenol oxidase-induced, such as laccase-induced, crosslinking via free amino acid-carrying polymers and bridging molecules, as defined above.
- the invention relates to the method of bonding soft and hard tissue through a kit and / or adhesive as defined above.
- the bonding of soft and hard tissue can be, among other things, the bonding of bone to bone.
- kits and / or adhesive according to the invention small bony fragments, which can not be fixed with screws because of their size or only insufficiently, are fixed with the kit and / or adhesive according to the invention.
- no second operation after healing of the fracture is required in the bonding by means of the kit and / or adhesive according to the invention.
- bones can be fixed to soft tissue.
- Cartilage grafts (e.g., from tissue culture), e.g. for the treatment of osteoarthritis, can be sufficiently fixed by means of the kit and / or adhesive according to the invention until it grows on the articular surface. It is particularly advantageous in this context that the kit and / or adhesive is gradually absorbed.
- bones can also be fixed to implants by means of the kit and / or adhesive according to the invention. Especially with osteoporotic bone, the holding power of screws is very reduced. By a large-area bonding of the outside of the bone with the implant (for example plate) by means of the kit and / or adhesive according to the invention, the holding force of the screws can be supported or screws can even be completely dispensed with. Cell vitality studies revealed good biocompatibility of the crosslinked product.
- the invention also encompasses in particular the use of the kit according to the invention, either with the two individual components “bridging molecules” and “polyphenol oxidases” or particularly preferably with the three individual components “polymers with at least one free amino group",
- the invention also includes, in particular, the use of the kit according to the invention for the production of the adhesive for the bonding of soft and hard tissue as well as the bonding of bone with implants (eg plate), as described above.
- Crosslinking by means of the combination according to the invention, in particular the linking of peptide sequences which contain the amino acids relevant for an adhesive action, with the aid of the enzyme system (lignolytic) polyphenol oxidase, such as laccase, produces a very strong bond in various fields of use, but in the course of the healing process can be absorbed.
- the initial hardening phase, combined with high adhesive properties, and the time-dependent slow absorption in the body in advanced healing processes are of particular advantage.
- the adhesive or kit can be used for bone fractures, for fixation of vascular prostheses, biodegradable implants, catheters, stents and other materials.
- the invention also encompasses the use of the kit according to the invention, either with the two individual components "bridging molecules” and “polyphenol oxidases” or particularly preferably with the three individual components “polymers having at least one free amino group", “bridging molecules” and “polyphenol oxidases” as defined above for the preparation of an adhesive for bonding fractures and / or for fixation of vascular prostheses, biodegradable implants, catheters, stents and other materials.
- the acceptance of the implanted material by the bone cells is of fundamental importance.
- this also applies to the adhesive used. Due to the rapid colonization with osteoblasts and their subsequent maturation promotes new bone formation and shortens the healing process. Implants are therefore manufactured with microstructured surfaces.
- the kit or adhesive according to the invention preserves this structure and supports the formation of new bone.
- collagen which is indispensable for bone healing, the amino acids lysine and proline are necessary.
- (lysine-tyrosine) n used as a polymer.
- lysine is present at the splice site in high concentration. This results in a positive influence on bone formation.
- the extracellular matrix formed is recognized by integrins such as ⁇ l ⁇ 1 or ⁇ 3 ⁇ 1 from the RDG sequence (Arg-Gly-Asp). This initiates a signal cascade that triggers changes in the cytoskeleton in the cell and switches between the proliferative stage and the stage of differentiation.
- the protein matrix formed also serves to store calcium salts.
- the invention is directed to novel zeolite granules which are suitable for haemostasis and can be used singly or supplementarily in the kit according to the invention.
- the novel zeolite granules in particular achieve a rapid bonding of wound edges.
- the novel zeolite granules are zeolite granules which have at least 70% by weight of zeolite, in particular with fractions of clinoptilolite, chabazite and mordenite, and a micropore space with an average pore size of 0.3 to 0.5 nm.
- these are zeolite granules hydrate-free, this state is preferably achieved after drying and pre-crushing by a gentle dehydration at temperatures below 200 ° C. In the case of gentle dehydration, in particular different temperature intervals below 200 ° C are used.
- Particular preference is given to using zeolite granules which originate from the fraction with grain size 0.8-0.2 mm.
- the present invention also encompasses the zeolite granules according to the invention as a medical device or as a medicament and the use of the zeolite granules according to the invention for producing a medical device and / or a medicament for haemostasis.
- classification as a pharmaceutical preparation or as a medical device, depending on national law, is possible.
- Mineral substance can be completely removed in, for example, by detachment of the scab-like wound cover and suction of the residues. It is possible in this embodiment of the invention to coat the zeolites in an envelope e.g. based on cellulose or on a textile basis or based on a collagen fleece. Thus, the subsequent complete removal is particularly easy.
- the invention also encompasses the use of the zeolite granules according to the invention for producing the adhesive according to the invention for bonding wounds and for sealing anastomoses and patches on vessels or on hollow organs.
- the tear strength of the wound closure is lower than with conventional fibrin adhesives.
- the present invention is directed in a further embodiment to a kit which comprises the following individual components: a) polymers having at least one free amino group, b) bridging molecules selected from the group consisting of monocyclic ortho-dihydroxyaromatics, monocyclic para-dihydroxyaromatics, bicyclic monohydroxyaromatics , polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic dihydroxyaromatics, bicyclic trihydroxyaromatics, polycyclic trihydroxyaromatics, and mixtures thereof, c) polyphenol oxidases, in particular lignolytic polyphenol oxidases, and d) hemostatic minerals, in particular zeolite granules as described above, where the group consisting of monocyclic ortho-dihydroxyaromatics, monocyclic para-dihydroxyaromatics, bicyclic monohydroxyaromatics , polycyclic monohydroxyaromatics, bicyclic dihydroxyaromatics, polycyclic di
- the kit is based in particular on natural zeolite fine granules and on polyphenol oxidases (in particular laccase) with which the poly- or oligopeptides can be crosslinked.
- the natural zeolite fine granules are not in contact with the other individual components of the kit, ie it is preferred that the zeolites are separately packaged and thus used separately.
- the natural zeolite fine granules ensure concentration due to their high capillary power of coagulation factors for rapid wound closure. Thereafter, the zeolites can be easily removed again. A blood-free, clear surgical field is obtained.
- a further advantage is that correction possibilities, for example before the addition of the uncrosslinked polymers - if desired - still exist.
- the kit of the invention is an alternative to both electrocoagulation and wound closure with needle and suture.
- the present invention also encompasses the use of the kit according to the invention, which comprises the individual components b) to d) or more preferably a) to d), for the production of an adhesive for the closure of wounds.
- the invention also includes, in particular, the use of the kit according to the invention, which comprises the individual components b) to d) or more preferably a) to d), for the production of the adhesive for the bonding of soft and hard tissue and the bonding of bones with implants (eg plate) as described above.
- the present invention is also directed to an adhesive comprising components b) to d) or more preferably a) to d), as described above, wherein at least components b) to c) or a) to c) , Preferably all individual components b) to d) or a) to d), are in contact with each other.
- the high capillary force of the natural zeolite fine granules is also of particular importance for use in wound care, in particular for the treatment of wounds that are difficult to heal and have already become chronic. Particularly indicated is the use of the natural zeolite fine granules, in wounds with an exudation, ie a leakage of blood components to an inflamed wound. Often, exudation is an indication of infection from an injury.
- the microporous structure of the zeolite granules obtained according to the invention enables the uptake of wound exudate to be released in excess in the case of "weeping" wounds a moist atmosphere over the wound, which is important for wound healing.
- zeolites with a pore size of 0.3 to 0.5 nm, in particular in a ratio of 1:10 to 10: 1 can be mixed with the biomass from aquatic organisms, as defined below, without haemostatic action or capillary action to lose.
- the use of the novel zeolite granules can be extended by substituting these materials with biomass. Consequently, the present invention also encompasses the zeolite granules according to the invention which additionally contain biomass, in particular in the ratio of zeolite to biomass of from 1:10 to 10: 1.
- the biomass is lyophilized and ground and / or according to the technical teaching of Lukowski et al .: Pharmaceutically or cosmetically active agents obtained from lipid-containing marine organisms. US 10 / 507,061 is processed.
- Polysaccharides advantageously of poly-N-acetyl-glucosamines or chitosan, have a large internal surface area. Due to absorption to this large area, there is a synergistic effect in the concentration of coagulation factors as well as in the uptake of wound secretions as well as bacterial toxins. In addition, these polysaccharides have an immunostimulating effect.
- freeze-dried biomasses of the green alga Chlamydomonas and / or the microalgae Spirulina and / or Anabaena are used.
- activation of the fibrin system results in a solid scab-like covering that reliably protects the wound from bacterial infection. This cover is repelled in the course of wound healing.
- the fine granules of natural zeolites and microalgae biomass can also be used to treat highly infectious, weeping wounds.
- kit and / or adhesive may contain the inventive combination of zeolite granules and biomass in all embodiments described in detail above.
- Example 1 Preparation of the natural zeolite fine granules
- Selective minerals with> 70% zeolite content preferably clinoptilo- lite, chabazite and mordenite, are obtained after drying and pre-comminution by fractionation with grain size 0.8-0.2 mm.
- the requirements are US Pharmacop. or Europ. Pharmacorp. to fulfill.
- gentle thermal treatment at selected temperature intervals at temperatures ⁇ 200 ° C a partial dehydration takes place to obtain the crystal lattice structure.
- Example 2 Testing of the microporous volume and the particle size distribution
- the products prepared according to Example 1 have 25-50% micropore space (based on the total volume) and average nanopore diameters in the range 0.3-0.5 nm.
- Nanopore size and fine granulate structure allow maximum blood adsorption and rapid penetration of the adsorbent granules.
- the capillary force effect is 5 to 10 times higher than in the comparatively investigated commercial preparation CERDAC
- Example 3 Testing the fine granules for suitability for haemostasis
- Rats were anesthetized for this purpose. After opening of the abdominal cavity was made with the scalpel about a 1 cm long incision. The bleeding was filmed. The time to hemostasis was measured.
- hemostasis is achieved within 1 min (control without treatment up to 8 min). It forms a scab-like encrustation that protects the wound.
- Example 4 In vitro examination of the fine granules for suitability for haemostasis
- Acetate tissue as used for the preparation of wound dressings, is dripped with 2 mg of extract equivalent amount of extract solution and allowed to dry.
- the extracts were prepared using freeze-dried biomasses of the green alga Chlamydomonas, the microalgae Spirulina (B lue Biotech Büsum) and Anabaena (strain collection of the Institute of Pharmacy of the Ernst Moritz Arndt University Greifswald).
- the extractor DIONEX ASE 200 used for extraction with n-hexane.
- the extract solution was freed from the solvent by means of a rotary evaporator.
- no methicillin-resistant strains of Staphylococcus triggers (MRSA) which are feared as causative agents of wound infections, can be detected.
- MRSA methicillin-resistant strains of Staphylococcus triggers
- germ growth was reduced to 10 to 20% of the starting bacterial count.
- Example 6 Production of fine granules from natural zeolites and the biomass of microalgae
- the mineral granules produced according to Example 1 microalgae biomass with a lipid content> 20% in the ratio 1:10 to 10: 1 are added. This prevents the germ colonization of the wounds.
- Example 7 Testing the fine granules for suitability for haemostasis and wound closure
- Rats were anesthetized for this purpose. After opening the abdomen, the scalpel was used to make a cut of about 1 cm. The bleeding was filmed. The time to hemostasis was measured. The wound closure was assessed visually. Result:
- hemostasis is achieved within 1 min (control up to 8 min). It forms a scab-like encrustation that protects the wound.
- wound closure is better with fine granules on mineral / algae biomass basis than with the use of the exclusively mineral-based preparations.
- Example 8 Preparation of the adhesive prepolymers and performing the adhesive reaction for soft tissue and hard tissue adhesion
- bridging molecule 2 2,5-dihydroxy-N- (2- hydroxyethyl) benzamide
- laccase 5 the enzyme laccase
- Adhesion occurs through the enzymatic reaction of the laccase with the bridging molecule linked to the oligopeptide.
- the tissue parts to be examined had to be fixed beforehand. Porcine soft tissue was fixed to polymethylmethacrylate (PMMA) specimen holders with cyanoacrylate adhesive, or bone plates of bovine bone were clamped in mechanical clamps. Subsequently, the adhesive mixture to be examined (see Example 6) was applied to the fabric. The soft tissue was after 10 minutes the strength of the adhesive joint under tensile stress on the testing machine Zwick BZ2.5 / TN1 S (test speed: 10 mm / min) determined. The mechanical testing of the adhesive joint after hard tissue bonding was carried out under tensile shear stress at a test speed of 5 mm / min.
- PMMA polymethylmethacrylate
- Example 10 Diffusion-inhibition test with the inventively doped collagen fleece in comparison to a nonwoven doped with a conventional antibiotic.
- Polymer biomaterials (1 cm 2 each) are named after Contrib. Plasma Phys. 41, 2001, 562-572 functionalized in ammonia plasma. Thereafter, the reaction with 2,5-dihydroxy-N- (2-hydroxyethyl) benzamide (12.5 mM) under the Influence of laccase (0.32 U (156 nmol ml "1 min " 1 ).) The solvent content of methanol was 10% (v / v).
- the control counts 120 germs / cm. Under the coated surfaces no germs can be detected.
- Example 12 Use of the combination according to the invention for the treatment of bleeding wounds.
- Rats are anesthetized as in Example 7, the abdominal cavity opened and one
- Collagen film (DOT GmbH) was fixed on a flat surface.
- the collagen film was divided into 8 segments (4 each in two rows) and the adhesive was mixed together directly on the film (taking advantage of the surface tension).
- the glue was dissolved in phosphate citrate buffer.
- the adhesive protein had an MW of about 4000D
- the bonding also takes place without the addition of adhesive proteins.
- the adhesive proteins increase the binding force.
- Example 14 Mixture of a collagen solution with the adhesive Microscopically, a strong structuring can be seen after mixing the collagen solution with the adhesive. The dissolved and random collagen molecules are parallelized to form fibers.
- citrate-phosphate buffer control
- adhesive solution buffer, laccase, laccase substrate
- the collagen has been permanently bonded to the ground.
- the cell adhesion was carried out on 60 mm TCPS cell culture dish, which was coated according to Example 15 with collagen. After staining the cells with crystal violet, the evaluation was carried out with the CellExplorer
- the FL cells are bound more strongly (see Figure 1)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007800051590A CN101384284B (zh) | 2006-02-09 | 2007-02-09 | 医疗用途的粘合剂和止血剂 |
EP07711497.3A EP1981553B1 (de) | 2006-02-09 | 2007-02-09 | Kleber für medizinische anwendungen und mittel zur blutstillung |
JP2008553686A JP2009525795A (ja) | 2006-02-09 | 2007-02-09 | 医療用接着剤および止血剤 |
US12/223,772 US7923003B2 (en) | 2006-02-09 | 2007-02-09 | Adhesive for medical applications and means for haemostasis |
CA2637794A CA2637794C (en) | 2006-02-09 | 2007-02-09 | Adhesive for medical applications and means for haemostasis |
AU2007213923A AU2007213923C1 (en) | 2006-02-09 | 2007-02-09 | Adhesive for medical applications and means for haemostasis |
US13/037,850 US8440209B2 (en) | 2006-02-09 | 2011-03-01 | Adhesive for medical applications and means for haemostasis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006006904A DE102006006904A1 (de) | 2006-02-09 | 2006-02-09 | Neue Mittel zur Blutstillung und Klebstoffe für medizinische Anwendungen |
DE102006006904.8 | 2006-02-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/223,772 A-371-Of-International US7923003B2 (en) | 2006-02-09 | 2007-02-09 | Adhesive for medical applications and means for haemostasis |
US13/037,850 Continuation US8440209B2 (en) | 2006-02-09 | 2011-03-01 | Adhesive for medical applications and means for haemostasis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007090673A2 true WO2007090673A2 (de) | 2007-08-16 |
WO2007090673A3 WO2007090673A3 (de) | 2007-12-13 |
Family
ID=38261578
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2007/000192 WO2007090373A2 (de) | 2006-02-09 | 2007-02-02 | Neue klebstoffe für medizinische anwendungen |
PCT/EP2007/001131 WO2007090673A2 (de) | 2006-02-09 | 2007-02-09 | Kleber für medizinische anwendungen und mittel zur blutstillung |
PCT/DE2007/000241 WO2007090384A2 (de) | 2006-02-09 | 2007-02-09 | Klebstoffe und klebeverfahren |
PCT/EP2007/051251 WO2007090880A2 (de) | 2006-02-09 | 2007-02-09 | Resorbierbares calciumphosphatbasierendes biopolymervernetztes knochenersatzmaterial |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2007/000192 WO2007090373A2 (de) | 2006-02-09 | 2007-02-02 | Neue klebstoffe für medizinische anwendungen |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2007/000241 WO2007090384A2 (de) | 2006-02-09 | 2007-02-09 | Klebstoffe und klebeverfahren |
PCT/EP2007/051251 WO2007090880A2 (de) | 2006-02-09 | 2007-02-09 | Resorbierbares calciumphosphatbasierendes biopolymervernetztes knochenersatzmaterial |
Country Status (10)
Country | Link |
---|---|
US (3) | US7923003B2 (de) |
EP (5) | EP3050579B1 (de) |
JP (2) | JP2009525795A (de) |
CN (2) | CN101384284B (de) |
AT (1) | ATE504317T1 (de) |
AU (2) | AU2007213663A1 (de) |
CA (2) | CA2640771C (de) |
DE (2) | DE102006006904A1 (de) |
ES (2) | ES2771824T3 (de) |
WO (4) | WO2007090373A2 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
US8921109B2 (en) | 2005-09-19 | 2014-12-30 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
DE102006048833A1 (de) | 2006-10-16 | 2008-04-17 | Universität Rostock | Behandlung von Osteoporose |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
DE102007038125A1 (de) * | 2007-08-03 | 2009-02-05 | Aesculap Ag | Kombination zum Verkleben von biologischen Geweben |
DE102007045066A1 (de) * | 2007-09-20 | 2009-04-02 | Mike Ehrlich | Material zur Blutstillung enthaltend synthetische Peptide oder Polysaccharide |
WO2009111069A1 (en) | 2008-03-05 | 2009-09-11 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US8758791B2 (en) * | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
US20110243913A1 (en) * | 2010-04-06 | 2011-10-06 | Orthovita, Inc. | Biomaterial Compositions and Methods of Use |
JP5545985B2 (ja) * | 2010-06-03 | 2014-07-09 | コニシ株式会社 | ポリ乳酸系接着剤及びその製造方法 |
WO2012062360A1 (en) | 2010-11-10 | 2012-05-18 | Stryker Trauma Gmbh | Polymeric bone foam composition and method |
AU2012272748C1 (en) | 2011-06-23 | 2017-06-15 | Stryker Corporation | Prosthetic implant and method of implantation |
US9765205B2 (en) | 2011-08-24 | 2017-09-19 | Algix, Llc | Macrophyte-based bioplastic |
US8791219B2 (en) | 2012-03-23 | 2014-07-29 | California Institute Of Technology | Rapidly crosslinkable adhesives for biomedical applications |
DE102012107535A1 (de) | 2012-08-16 | 2014-02-20 | Bess Pro Gmbh | Bioresorbierbare Klebstoffe und deren Verwendung im medizinischen Bereich |
US9427334B2 (en) | 2013-03-08 | 2016-08-30 | Stryker Corporation | Bone pads |
WO2015104565A2 (en) * | 2014-01-08 | 2015-07-16 | Wu, Xiu Ying | Bio-adhesives |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US20170002240A1 (en) * | 2015-07-01 | 2017-01-05 | H.B. Fuller Company | Adhesive composition based on polylactide polyols |
EP3231420A1 (de) * | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Missbrauchsverhindernde pharmazeutische zusammensetzungen |
AR108339A1 (es) * | 2016-04-27 | 2018-08-08 | Cryovac Inc | Película que tiene un depurador de oxígeno y un depurador de compuesto organoléptico volátil |
AU2018266193B2 (en) * | 2017-05-10 | 2024-03-28 | Marquette University | Medical and dental integrated multiphasic biomaterials for single or multi-tissue reconstruction/regeneration |
DE102018126394B4 (de) | 2018-10-23 | 2020-12-24 | Universität Rostock | Probiotika enthaltendes Depotsystem für dentale Anwendungen |
CN109593736A (zh) * | 2018-12-19 | 2019-04-09 | 江苏德和生物科技有限公司 | 一种茶黄素生产用固定化多酚氧化酶的工业制备方法 |
CN110624136B (zh) * | 2019-10-08 | 2021-12-17 | 威高集团有限公司 | 一种可降解医用复合材料及其制备方法和应用 |
CN111205817A (zh) * | 2020-01-08 | 2020-05-29 | 山西大学 | 一种无醛酶改性糖-大豆基复合木材胶黏剂及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542115A (en) * | 1981-08-17 | 1985-09-17 | Degussa Aktiengesellschaft | Zeolite granulate, process for its production |
US5015677A (en) * | 1986-04-25 | 1991-05-14 | Bio-Polymers, Inc. | Adhesives derived from bioadhesive polyphenolic proteins |
WO2000069480A1 (en) * | 1999-05-12 | 2000-11-23 | D & E Cryo Cc | Ceramic wound treatment device |
WO2003035122A1 (de) * | 2001-10-24 | 2003-05-01 | Aesculap Ag & Co. Kg | Zusammensetzung aus einem aminoruppen tragenden polymer und einem aldehyd mit mindestens drei aldehydgruppen |
US20030187387A1 (en) * | 1997-10-22 | 2003-10-02 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5831901B2 (ja) * | 1979-05-10 | 1983-07-09 | 忠敬 駒木根 | 無機質防菌防腐用飼料添加剤 |
IT1157273B (it) * | 1982-05-07 | 1987-02-11 | Anic Spa | Composizioni termoplastiche a base di polimeri organici non polari e zeoliti in forma acida, dotate di tenace adesione a metalli ed oggetti compositi ottenibili mediante le medesime |
US4822349A (en) * | 1984-04-25 | 1989-04-18 | Hursey Francis X | Method of treating wounds |
ES2025572T3 (es) * | 1986-04-25 | 1992-04-01 | Bio-Polymers, Inc. | Procedimiento para fabricar adhesivos derivados de proteinas polifenolicas bioadhesivas. |
US5140949A (en) * | 1989-09-19 | 1992-08-25 | Mobil Oil Corporation | Zeolite-clay composition and uses thereof |
JPH0479845A (ja) * | 1990-07-20 | 1992-03-13 | Hitachi Kako Kk | 飼料の粒状添加材 |
JPH05337151A (ja) * | 1992-06-11 | 1993-12-21 | Terumo Corp | 創傷被覆材 |
AU7109494A (en) * | 1993-06-16 | 1995-01-03 | Enzon, Inc. | Conjugated biodhesives |
US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5494744A (en) * | 1994-10-12 | 1996-02-27 | Kimberly-Clark Corporation | Method of applying a protein coating to a substrate and article thereof |
GB9523581D0 (en) * | 1995-11-17 | 1996-01-17 | British Textile Tech | Cross-linking |
JPH1045608A (ja) * | 1996-04-17 | 1998-02-17 | Toya Seishi Kk | ゼオライトを含有する創傷治療剤 |
GB2326827B (en) * | 1997-06-30 | 2002-02-20 | Johnson & Johnson Medical | Use of molecular sieves to promote wound healing |
ES2293719T3 (es) * | 1998-03-06 | 2008-03-16 | Baxter International Inc. | Cabezal mezclador con turbulencia para un aplicador de adhesivo quirurgico y cabezal de pulverizacion correspondiente. |
US6884230B1 (en) * | 1998-03-09 | 2005-04-26 | Baxter International Inc. | Dispensing head for a tissue sealant applicator and process of use |
JP4137224B2 (ja) | 1998-03-31 | 2008-08-20 | 天野エンザイム株式会社 | 酵素による蛋白質の架橋法 |
GB2336156B (en) * | 1998-04-09 | 2003-05-07 | Mars Uk Ltd | Adhesives |
EP1731175B1 (de) | 1998-11-12 | 2009-09-30 | International Manufacturing Group, Inc. | Hämostatische vernetzte Dextranperlen verwendbar zur schnellen Blutgerinnung und Hämostase |
DE19958526A1 (de) * | 1998-12-17 | 2000-06-21 | Henkel Kgaa | Polyester-Polyurethan-Klebstoff und seine Verwendung |
EP1169922A1 (de) * | 2000-07-03 | 2002-01-09 | Instituut Voor Agrotechnologisch Onderzoek (Ato-Dlo) | Methode für enzymatisches Vernetzen von Proteinen und phenolischen Polymeren |
US20020114795A1 (en) * | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
DE10100404A1 (de) | 2001-01-05 | 2002-07-11 | Bayer Ag | Verfahren zur Herstellung von Polycarbonat |
WO2003008376A2 (en) * | 2001-07-20 | 2003-01-30 | Northwestern University | Adhesive dopa-containing polymers and related methods of use |
DE10310021A1 (de) * | 2002-02-28 | 2003-10-23 | Lukowski Gerold | Pharmazeutisch oder kosmetisch wirksame Mittel aus liqidhaltigen marinen Oragnismen |
AU2003304348A1 (en) * | 2002-03-15 | 2005-02-04 | The Trustees Of The University Of Pennsylvania | Fibrous composite for tissue engineering |
JP2003305117A (ja) * | 2002-04-18 | 2003-10-28 | Toya Seishi Kk | 電気石充填チューブ |
US7060798B2 (en) * | 2002-05-13 | 2006-06-13 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Modified protein adhesives and lignocellulosic composites made from the adhesives |
WO2003106539A1 (ja) * | 2002-06-17 | 2003-12-24 | 日本電気株式会社 | 生分解性樹脂、生分解性樹脂組成物、生分解性成形体、生分解性樹脂の製造方法 |
DE10240775A1 (de) | 2002-08-30 | 2004-03-11 | Röhm GmbH & Co. KG | Verfahren zur Entfernung von Metallionen aus Polymeren oder Polymerlösungen |
DE10302096B4 (de) * | 2003-01-16 | 2005-03-17 | Coty B.V. | Kosmetische selbsterwärmende Produkte und deren Verwendung |
EP1667623B1 (de) * | 2003-09-12 | 2010-11-24 | Z-Medica Corporation | Teilweise hydriertes hämostatisches mittel |
WO2005027808A1 (en) * | 2003-09-12 | 2005-03-31 | Z-Medica Corporation | Calcium zeolite hemostatic agent |
WO2005062868A2 (en) * | 2003-12-19 | 2005-07-14 | Osteotech, Inc. | Tissue-derived mesh for orthopedic regeneration |
JP4269073B2 (ja) * | 2004-03-11 | 2009-05-27 | 岡井 洋 | 反応性ホットメルト硬化性組成物及び硬化方法 |
JP2005287913A (ja) * | 2004-04-02 | 2005-10-20 | Suikoh Topline:Kk | ハイブリッド型ミネラル臭気・有害成分吸着除去材 |
DE102004026904A1 (de) * | 2004-06-01 | 2005-12-22 | Basf Ag | Hochfunktionelle, hoch- oder hyperverzweigte Polyester sowie deren Herstellung und Verwendung |
JP2006008804A (ja) * | 2004-06-24 | 2006-01-12 | Bridgestone Corp | 接着剤、その製造方法および使用方法、および、この接着剤を用いたホース |
JP2006008882A (ja) * | 2004-06-28 | 2006-01-12 | Sanyo Chem Ind Ltd | 帯電防止性感圧接着剤 |
WO2006016809A1 (en) * | 2004-08-12 | 2006-02-16 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | A method for enzymatic cross-linking of a protein, cross-linked protein thus obtained and use thereof. |
JP2009528080A (ja) * | 2006-02-27 | 2009-08-06 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | 硬化性骨セメント |
-
2006
- 2006-02-09 DE DE102006006904A patent/DE102006006904A1/de not_active Withdrawn
-
2007
- 2007-02-02 EP EP15202504.5A patent/EP3050579B1/de active Active
- 2007-02-02 ES ES15202504T patent/ES2771824T3/es active Active
- 2007-02-02 EP EP07702422.2A patent/EP1984032B1/de active Active
- 2007-02-02 ES ES07702422.2T patent/ES2566054T3/es active Active
- 2007-02-02 WO PCT/DE2007/000192 patent/WO2007090373A2/de active Application Filing
- 2007-02-09 CN CN2007800051590A patent/CN101384284B/zh active Active
- 2007-02-09 AU AU2007213663A patent/AU2007213663A1/en not_active Abandoned
- 2007-02-09 AT AT07704469T patent/ATE504317T1/de active
- 2007-02-09 WO PCT/EP2007/001131 patent/WO2007090673A2/de active Application Filing
- 2007-02-09 EP EP07721909A patent/EP1987111A2/de not_active Withdrawn
- 2007-02-09 DE DE502007006879T patent/DE502007006879D1/de active Active
- 2007-02-09 CA CA2640771A patent/CA2640771C/en not_active Expired - Fee Related
- 2007-02-09 US US12/223,772 patent/US7923003B2/en active Active
- 2007-02-09 EP EP07704469A patent/EP1981552B1/de not_active Not-in-force
- 2007-02-09 WO PCT/DE2007/000241 patent/WO2007090384A2/de active Application Filing
- 2007-02-09 JP JP2008553686A patent/JP2009525795A/ja active Pending
- 2007-02-09 JP JP2008553771A patent/JP2009525799A/ja not_active Withdrawn
- 2007-02-09 WO PCT/EP2007/051251 patent/WO2007090880A2/de active Application Filing
- 2007-02-09 US US12/223,899 patent/US20090280179A1/en not_active Abandoned
- 2007-02-09 CN CNA2007800047684A patent/CN101378789A/zh active Pending
- 2007-02-09 EP EP07711497.3A patent/EP1981553B1/de active Active
- 2007-02-09 AU AU2007213923A patent/AU2007213923C1/en active Active
- 2007-02-09 CA CA2637794A patent/CA2637794C/en active Active
-
2011
- 2011-03-01 US US13/037,850 patent/US8440209B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542115A (en) * | 1981-08-17 | 1985-09-17 | Degussa Aktiengesellschaft | Zeolite granulate, process for its production |
US5015677A (en) * | 1986-04-25 | 1991-05-14 | Bio-Polymers, Inc. | Adhesives derived from bioadhesive polyphenolic proteins |
US20030187387A1 (en) * | 1997-10-22 | 2003-10-02 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant |
WO2000069480A1 (en) * | 1999-05-12 | 2000-11-23 | D & E Cryo Cc | Ceramic wound treatment device |
WO2003035122A1 (de) * | 2001-10-24 | 2003-05-01 | Aesculap Ag & Co. Kg | Zusammensetzung aus einem aminoruppen tragenden polymer und einem aldehyd mit mindestens drei aldehydgruppen |
Non-Patent Citations (1)
Title |
---|
See also references of EP1981553A2 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1981553B1 (de) | Kleber für medizinische anwendungen und mittel zur blutstillung | |
Rahimnejad et al. | Mussel-inspired hydrogel tissue adhesives for wound closure | |
Thi et al. | Engineered horseradish peroxidase-catalyzed hydrogels with high tissue adhesiveness for biomedical applications | |
Duarte et al. | Surgical adhesives: Systematic review of the main types and development forecast | |
US5350798A (en) | Absorbable tissue adhesives | |
He et al. | Mussel-inspired antimicrobial gelatin/chitosan tissue adhesive rapidly activated in situ by H2O2/ascorbic acid for infected wound closure | |
KR101650273B1 (ko) | 무세포 진피의 가교 및 생체 이식 또는 삽입용 조성물의 제조방법 | |
EP1438079A1 (de) | Zusammensetzung aus einem aminogruppen tragenden polymer und einem aldehyd mit mindestens drei aldehydgruppen | |
KR101523878B1 (ko) | 입자형 무세포 진피와 히알루론산이 가교된 생체 이식용 조성물의 제조방법 | |
EP2185207B1 (de) | Kombination zum verkleben von biologischen geweben | |
Hsu et al. | Fabrication and evaluation of a biodegradable cohesive plug based on reconstituted collagen/γ‐polyglutamic acid | |
WO2009037571A2 (de) | Material zur blutstillung enthaltend synthetische peptide oder polysaccharide | |
CN112386740A (zh) | 一种成纤维细胞生长因子自粘性人工硬膜修补片及其制备方法 | |
DE102014226098A1 (de) | Mehrkomponentenklebstoff zur Herstellung eines Adhäsivhydrogels | |
WO2024003602A1 (en) | Bioadhesives, method of preparation and uses thereof | |
CN116920162A (zh) | 水凝胶组合物、水凝胶及其制备方法和用途 | |
Gosain et al. | Use of tissue glue: current status | |
CN117482276A (zh) | 一种抗菌组织贴片及其制备方法与应用 | |
CN117298326A (zh) | 一种基于重组贻贝粘蛋白的组织粘合剂及其应用 | |
DE19928371A1 (de) | Zubereitung zur Stillung von Blutungen | |
Sethumadhavan et al. | Investigations on inducible nitric oxide synthase (iNOS) gene expression and SEM analysis during the interaction of a novel tissue adhesive with J774A. 1 mouse macrophage cells | |
DE102012107535A1 (de) | Bioresorbierbare Klebstoffe und deren Verwendung im medizinischen Bereich |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007213923 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2637794 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6448/DELNP/2008 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2007711497 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007711497 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008553686 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780005159.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007213923 Country of ref document: AU Date of ref document: 20070209 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2007213923 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12223772 Country of ref document: US |